HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a price target of $15.
August 09, 2023 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Praxis Precision Medicine's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $15.
The reiteration of a 'Buy' rating by a reputable analyst like Douglas Tsao from HC Wainwright & Co. is a positive signal for investors. The maintained price target of $15 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100